Pricing assessments have become one of the most frequent requests I get in the competitive intelligence space, and for good reasons. These projects aren’t like the usual qualitative intel-gathering exercises. They’re deep, data-driven, and if done right, can directly influence…

Over the years, I’ve seen Voice of Customer (VOC) perception studies evolve from “nice-to-haves” into must-have tools, especially for competitive intelligence teams. Yes, we all want to know what our competitors are doing. But here’s the truth: what customers think…

I still remember when immuno-oncology first started making waves. The buzz around checkpoint inhibitors was electric—PD-1, PD-L1, CTLA-4—suddenly, we were talking about cancer therapies that could unlock the immune system instead of just targeting the tumor. Fast forward a decade,…

As global trade dynamics shift yet again, the pharmaceutical industry is bracing for impact. Recent tariff developments—particularly the reintroduction of sweeping U.S. import duties—are prompting executives across healthcare and life sciences to revisit their sourcing strategies and cost structures. But…

When I first started working in the rare disease and gene therapy space, I thought the science would be the hardest part to wrap my head around. And don’t get me wrong—it’s complex. But what I didn’t fully appreciate at…

I’ll admit it—there was a time when neuroscience felt like a graveyard of pharma ambitions. I remember the wave of program terminations, the clinical failures, and the retreat from Alzheimer’s and Parkinson’s pipelines that felt almost industry wide. For a…

Picture this: You’re in a high-stakes chess match. The room is silent. The tension is thick. Every move counts. But instead of thinking ahead, you’re fixated on where your opponent used to be five turns ago. You can guess what…

A Preview of My Upcoming Talk: Presenting Pricing Insights That Resonate with Leaders Pricing strategies often rely on robust data—carefully researched, meticulously analyzed, and expertly compiled. Yet, even the most data-driven pricing recommendations can be met with hesitation, skepticism, or…

Introduction Background Drug pricing reform in the U.S., driven by legislative changes such as the Inflation Reduction Act (IRA) and ongoing policy initiatives, is set to significantly alter the pharmaceutical competitive landscape. These changes will influence market access, pricing strategies,…